Based on the results of RELATIVITY‐047, the immunotherapy regimen of relatlimab (a LAG‐3 inhibitor) in combination with Nivolumab was approved by the US FDA in March 2022 for the treatment of unresectable or metastatic melanoma [248]. The gene discussed is LAG3; the disease is metastatic melanoma.